L3VLUP
ProSign in

EXEL · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EXELAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EXEL
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterEXELAMGN
Q3 202018 holders, $1.8bn16 holders, $16.3bn
Q4 202011 holders, $1.2bn19 holders, $14.0bn
Q1 202113 holders, $1.3bn16 holders, $14.5bn
Q2 202110 holders, $976m23 holders, $13.8bn
Q3 202113 holders, $1.1bn24 holders, $11.6bn
Q4 20219 holders, $922m21 holders, $10.4bn
Q1 202210 holders, $1.2bn23 holders, $9.9bn
Q2 202212 holders, $1.4bn28 holders, $9.7bn
Q3 202211 holders, $630m21 holders, $7.9bn
Q4 202211 holders, $714m24 holders, $9.3bn
Q1 202312 holders, $1.1bn22 holders, $8.4bn
Q2 202310 holders, $976m26 holders, $7.4bn
Q3 202312 holders, $1.1bn26 holders, $8.7bn
Q4 202313 holders, $1.2bn24 holders, $8.4bn
Q1 202411 holders, $1.2bn25 holders, $6.7bn
Q2 202411 holders, $1.1bn20 holders, $8.0bn
Q3 202412 holders, $1.3bn21 holders, $8.8bn
Q4 202413 holders, $1.8bn20 holders, $8.2bn
Q1 202513 holders, $2.0bn25 holders, $12.0bn
Q2 202513 holders, $2.1bn20 holders, $10.2bn
Q3 20259 holders, $2.1bn17 holders, $10.4bn
Q4 202511 holders, $2.3bn19 holders, $18.0bn
Q1 202612 holders, $2.3bn15 holders, $21.4bn
Q2 202615 holders, $3.1bn23 holders, $24.9bn
EXEL

Exelixis Inc

Holders
9
Reported value
$2.1bn
Buyers
5
Sellers
4

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
17
Reported value
$10.4bn
Buyers
8
Sellers
9

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 24 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EXEL (7)

AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Caxton Associates LLP, Farallon Capital Management LLC, First Eagle Investment Management LLC, Voloridge Investment Management LLC

Only AMGN (15)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →